Items Tagged ‘HR+’

June 7th, 2016

Treatment with Aromatase Inhibitors for 10 Years Improves Cancer-Free Survival in Breast Cancer

By

Among postmenopausal women with hormone-positive, early breast cancer, treatment with aromatase inhibitors (AIs) for 10 years significantly improves cancer-free survival, compared to the 5-year standard length of AI treatment.  However, quality of life issues, bone density concerns, and a patient’s risk of a recurrence should be taken into consideration to determine the optimal length of […]

View full entry

Tags: AIs, aromatase inhibitors, Breast Cancer, early-stage, hormone-positive, HR+, News, postmenopausal, Stage I Node Negative Breast Cancer, survival


October 9th, 2015

Abemaciclib Receives FDA Breakthrough Therapy Designation in Advanced Breast Cancer

By

The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to abemaciclib, a cyclin-dependent kinase (CDK) 4 and 6 inhibitor, for patients with refractory hormone-receptor-positive (HR+) advanced or metastatic breast cancer. According to the FDA, Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended […]

View full entry

Tags: abemaciclib, Breast Cancer, CDK, hormone-receptor positive, HR+, metastatic, Metastatic Breast Cancer, MONARCH 3, News, Recurrent Breast Cancer